Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2

Anticancer Research

Volumn 22, Issue 2 B, 2002, Pages 1061-1064

  Lissoni, P ^a   Bordin, V ^a   Vaghi, M ^a   Fumagalli, L ^a   Bordoni, A ^a   Mengo, S ^a   Bucovec, R ^a   Fumagalli, E ^a   Malugani, F ^a   Ardizzoia, A ^a   Giani, L ^a   Gardani, G S ^a   Tancini, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Immunotherapy; Interleukin 2; Renal cell cancer

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CANCER; MALE; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 0036322750     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cancer, cyokines, and cytotoxic cells: Interleukin-2 in the immunotherapy of human neoplasms
2. The immunotherapy and gene therapy of cancer
3. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis
4. Prognostic markers in interleukin-2 therapy
5. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy
6. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study
7. Interleukin-2
8. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
9. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
10. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients
11. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma
12. Immunological effects of interleukin-2, interleukin-12 or interleukin-2 plus interleukin-12 in metastatic cancer patients
13. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
14. The vascular endothelial growth factor family of polypeptides
15. Serum VEGF is an independent prognostic factor in patients wih metastatic renal carcinma treated with IL-2 and/or IFN: Analysis of the CRECY trial